Showing results (51-60 of 193) with videos related to

Sort By:
Pageof 20
European Journal of Haematology|February 19, 2015
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or olderSusana Vives, Albert Oriol, Sònia Piernas, et al.
Expert Review of Hematology|January 8, 2025
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature reviewDavid I Marks, Ryan D Cassaday, Josep-Maria Ribera, et al.
Leukemia & Lymphoma|April 12, 2003
Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprineJosé-Tomás Navarro, Josep-Maria Ribera, José-Luis Mate, et al.
Experimental Hematology|September 2, 2009
Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomasIgnasi Barba, Carolina Sanz, Angels Barbera, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 12, 2020
Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in SpainJosep Maria Ribera Santasusana, Alejandra de Andrés Saldaña, Nuria García-Muñoz, et al.
Leukemia & Lymphoma|October 9, 2010
Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infectionBlanca Xicoy, Josep-Maria Ribera, José-Luís Mate, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2019
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?Susanna Gassiot, Yolanda González, Mireia Morgades, et al.
International Journal of Hematology|December 7, 2007
Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapyJosé-Tomás Navarro, Josep-Maria Ribera, Albert Oriol, et al.
Leukemia & Lymphoma|October 1, 2005
Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patientsMontserrat Batlle, Josep-Maria Ribera, Albert Oriol, et al.
Annals of Hematology|May 1, 2014
Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosisJordi Juncà, Montse Garcia-Caro, Isabel Granada, et al.
Pageof 20